A2i Therapeutics secures seed funding from FutuRx and its investors – Johnson & Johnson Innovation (JJDC, Inc.), Takeda Ventures, OrbiMed Partners, Leaps by Bayer and the Israeli Innovation Authority – to develop novel small molecule immuno-oncology agents. SAN FRANCISCO, CA and NESS ZIONA, Israel – December 18, 2020 – Atomwise, the leader in using artificial […]
The $2.3M in grant funding from the Bill & Melinda Gates Foundation will support the development of multiple global health programs to advance novel antimalarial and anti-tuberculosis small molecule therapies in collaboration with the foundation’s global network SAN FRANCISCO, CA — October 6th, 2020 — Atomwise, the leader in using artificial intelligence (AI) for small […]
The partnership will develop new drug programs that advance GC Pharma’s global leadership in hemophilia and additional disease areas SAN FRANCISCO & YONGIN, South Korea–(BUSINESS WIRE)–Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today a partnership with GC Pharma (KRX: 006280), a South Korean biopharmaceutical company formerly known as Green Cross […]
New financing will enable Atomwise to further scale the largest artificial intelligence (AI)-driven drug discovery portfolio in history and expand $5 billion+ deal pipeline for small molecule drug discovery SAN FRANCISCO — August 11, 2020 — Atomwise, the company deciphering human disease via the largest AI-drug discovery portfolio, announced today that it has closed $123 […]
Atomwise democratizes access to its advanced AI technology with 15 research collaborations underway to enable academic researchers to discover novel therapies for this pandemic and those in the future. SAN FRANCISCO–(BUSINESS WIRE)–Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today it has fifteen research collaborations underway with leading global […]